deltatrials
Completed PHASE3 NCT00092495

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine

Sponsor: Merck Sharp & Dohme LLC

Conditions Cervical Cancer Genital Warts
Interventions V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Updated 8 times since 2017 Last updated: Dec 29, 2014 Started: Dec 31, 2002 Primary completion: Sep 30, 2004 Completion: Feb 28, 2009

Listed as NCT00092495, this PHASE3 trial focuses on Cervical Cancer and Genital Warts and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 8 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.